Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study
Most Cited Paper
in Virus-based gene therapy research
18 Months Post-Publication
Class of 2026
“Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/virus-based-gene-therapy-research/2026/
Topics
RGX-314 · gene therapy · Wet age-related macular degeneration · Subretinal Injection · phase 1/2a dose-escalation study · Wet age-related macular degeneration · Anti-VEGF · Ocular Gene Delivery · AAV8 vector · Subretinal Injection · choroidal neovascularization · Anti-VEGF · sustained VEGF inhibition · Dose escalation · retinal gene therapy
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Virus-based gene therapy research Papers, Class of 2026. https://pri.pepkio.com/top-papers/virus-based-gene-therapy-research/2026. Accessed 2026-07-20. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459